Approval of generic Dostinex

Download PDF Copy

Reviewed

Jul 10 2007

Barr Pharmaceuticals, Inc. has announced that its subsidiary Barr Laboratories, Inc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Pharmacia and Upjohn Company's Dostinex (cabergoline) tablets, 0.5 mg.

The Company's Abbreviated New Drug Application (ANDA) was acquired from Teva Pharmaceuticals Industries Ltd. in connection with the acquisition of Ivax by Teva in January 2006. The Company plans to launch a product that is supplied by Teva in September 2007.

Dostinex had annual sales of approximately $68 million for the twelve months ended May 2007, based on IMS sales data.

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Source:

http://www.barrlabs.com/

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Why Salmonella Dublin poses a food safety threat in beef and dairy

Eating more ultra-processed food raises your risk of lung cancer

Fast food’s grip on American diets weakens as younger adults cut back

Food scientists identify worst additives for longevity: flavours, sweeteners, and colourings top list

Scientists set out to map the world’s traditional food environments and their health impacts

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Food insecurity raises long COVID risk while SNAP support cuts it

Are all healthy diets equal or does food processing make a difference?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.